Applying AI in Early Clinical Development of New Drugs
AI is transforming many industries including healthcare and pharma. Where are the opportunities for AI in the early clinical development of new drugs, where scientific hypotheses first meet real patients in clinical trials? Can AI generate new insights to inform translational research or improve the efficiency of clinical trials? In this talk, I will highlight opportunities created by big data and AI, e.g., digital biomarkers for neurological diseases, and share my thoughts on what it will take to operationalize AI in drug development.
Dr. James Cai is the Head of Data Science at Roche Innovation Center New York, responsible for supporting drug discovery and development projects by leveraging big data and advanced analytics. Through exploration and mining of biomedical big data, e.g., those in genomics, electronic health records (EHRs), digital images, text documents and wearable devices, he and his team have made numerous discoveries that impacted drug projects at Roche via new insights and better decision making. James worked in the pharma industry for the past 18 years. He has been a bioinformatics scientist, software developer, business analyst, project manager, data scientist, and manager at Roche. James has a Ph.D. in Molecular Biology from Cornell University and a Master’s degree in Biomedical Informatics from Columbia University.